manholdingbacktime
1 April 2013AmericasGabriel Di Blasi

Generic battles: pay-for-delay in Brazil

So-called ‘pay-for-delay’ agreements, also known as reverse payment agreements, are settlements executed between pharmaceutical industries in which a holder of an expired or soon-to-expire patented drug pays its competitor in order to prevent it from producing and selling a corresponding generic drug for a certain period of time.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
10 April 2026   The 2026 panel has been chosen. With judges from Amgen, Pfizer, Eli Lilly, Takeda, Regeneron and law firms such as White & Case and Arnold & Porter, here’s who will be deciding this year’s winners.
Americas
7 April 2026   According to the settlement, MSN can maintain its challenge to several Bausch patents, while the details around potential product launch timings are unknown.
Americas
1 April 2026   After years of strict patent rules, Argentina is changing course. New IP reforms are putting the country back on the map, but how companies handle the transition will matter.